Novartis AG Stock News

AbbVie is a Dividend King with plenty of growth potential left. Novartis offers investors a high dividend yield and strong prospects.

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), AbbVie (ABBV) and Novartis (NVS) are worth retainin

Novartis CEO Vasant Narasimhan joins 'Money Movers' to discuss the company's quarterly earnings results, the company's warning about losing exclusivity in some products, and if the sector will be acti

Novartis (NVS) announced fourth-quarter results and guidance Wednesday that fell short of analyst's expectations, and the company also ended a study on an experimental blood cancer treatment. American

Novartis AG (NVS) Q4 2023 Earnings Call Transcript

Novartis' (NVS) earnings and sales miss estimates in the fourth quarter. The outlook for 2024 does not look promising as well.

Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Stre

Vas Narasimhan, CEO of Novartis, discusses fourth-quarter results, weight loss drugs and the company's U.S. targets.

Switzerland's Novartis on Wednesday updated its mid-term guidance, saying it expected sales to grow 5% per year until 2028, when adjusting for currency swings.

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Besides Wall Street's top -and-bottom-line estimates for Novartis (NVS), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the qu

Novartis' (NVS) key drugs, Entresto, Kisqali and Pluvicto, are likely to have fueled its top and bottom-line numbers in the fourth quarter.

The FDA directs companies like NVS, BMY, GILD and others to add "boxed warning" to the labels of their CAR T-cell immunotherapies after it identified adverse events.

One of the top topics at the World Economic Forum is generative AI, with endless discussions on how it can impact a broad range of sectors and businesses. Pharmaceutical drug development is one of tho

As investors, our job isn't to predict an unknowable future.